Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company Inc.

A-Mark Precious Metals ( ($AMRK) ) has provided an update. On November 21, 2025, A-Mark Precious Metals announced its decision to transfer the list...

A-Mark Precious Metals Shifts Listing to NYSE

In a report released yesterday, from Deutsche Bank maintained a Hold rating on Merck & Company, with a price target of $111.00. In addition to Deut...

Merck & Company (MRK) Gets a Hold from Deutsche Bank

Marker Therapeutics ( ($MRKR) ) has released its Q3 earnings. Here is a breakdown of the information Marker Therapeutics presented to its investors...

Marker Therapeutics Reports Q3 2025 Financial Results

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Merck & Company, with a price target of $95.00. Meacham covers the ...

Citi Sticks to Their Hold Rating for Merck & Company (MRK)

Marks Electrical Group Plc ( ($GB:MRK) ) has issued an announcement. Marks Electrical Group plc is responding to an investigation by the Competitio...

Marks Electrical Responds to CMA Investigation on Pricing Practices

Bernstein analyst Florent Cespedes maintained a Hold rating on Merck KGaA today and set a price target of €135.00. Cespedes covers the Healthcare s...

Bernstein Reaffirms Their Hold Rating on Merck KGaA (0O14)

DZ BANK AG analyst Peter Spengler maintained a Buy rating on Merck KGaA on November 13. The company’s shares closed last Friday at €121.45. Accordi...

DZ BANK AG Reaffirms Their Buy Rating on Merck KGaA (0O14)

Insiders have been trading these 5 stocks: (($LLY)), (($GM)), (($IONQ)), (($MRK)) and (($MARA)). Here is a breakdown of their recent trades and the...

Eli Lilly, GM, IonQ, Merck, MARA: Insider Moves Unveiled!

In a report released on November 13, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA, with a price target of €182.00. The com...

Kepler Capital  Reaffirms Their Buy Rating on Merck KGaA (0O14)

An update from Marker Therapeutics ( ($MRKR) ) is now available. Marker Therapeutics reported promising results from its APOLLO study, showing a 66...

Marker Therapeutics Announces Positive APOLLO Study Results and Strategic Advances

Traders will find all the latest earnings reports, economic data, and deals leading the stock market on Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

The latest update is out from A-Mark Precious Metals ( ($AMRK) ). On November 12, 2025, A-Mark Precious Metals, Inc. held its Annual Meeting of Sto...

A-Mark Precious Metals Holds Virtual Annual Meeting

Shore Capital analyst maintained a Hold rating on Marks Electrical Group Plc today and set a price target of p50.00. Currently, the analyst consens...

Marks Electrical Group Plc (MRK) Receives a Hold from Shore Capital

Marks Electrical Group Plc ( ($GB:MRK) ) has issued an announcement. Marks Electrical Group Plc reported a challenging first half of FY26, with a 9...

Marks Electrical Group Reports Challenging H1 FY26 Amid Strategic Realignment

Energy company TotalEnergies ($TTE) has signed a 15-year deal with tech giant Google ($GOOGL) to supply renewable electricity to its data centers i...

TotalEnergies (TTE) and Google Sign 15-Year Deal to Power Data Centers

Northland Securities analyst Greg Gibas maintained a Hold rating on A-Mark Precious Metals today and set a price target of $30.00. Gibas covers the...

Northland Securities Sticks to Its Hold Rating for A-Mark Precious Metals (AMRK)

Insiders have been trading these 5 stocks: (($JPM)), (($ADBE)), (($LLY)), (($MCD)) and (($MRK)). Here is a breakdown of their recent trades and the...

Insider Moves: JPMorgan, Adobe, Eli Lilly, McDonald’s, Merck

Last week’s earnings call didn’t deliver what Merck & Co. ($MRK) investors were hoping for. While the company posted what initially appeared to be ...

Merck’s (MRK) Fading Momentum Offers Quant Arbitrage Options Trade

Marker Therapeutics ( ($MRKR) ) has shared an announcement. Marker Therapeutics has appointed Kathryn Penkus Corzo to its Board of Directors, effec...

Marker Therapeutics Strengthens Board with New Appointment

In a report released yesterday, Craig Irwin from Roth MKM maintained a Buy rating on A-Mark Precious Metals, with a price target of $40.00. The com...

A-Mark Precious Metals (AMRK) Gets a Buy from Roth MKM

With the S&P 500 ($SPX) up 22.8% over the past six months and the Nasdaq ($NDX) surging an even stronger 36.0%, there’s no denying that equities ar...

How MRK, ABBV, and BMY Could Rescue Investor Portfolios in a Downturn

In a report released today, Alexander Goldfarb from Piper Sandler maintained a Buy rating on Newmark Group, with a price target of $19.00. The comp...

Newmark Group (NMRK) Gets a Buy from Piper Sandler

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Merck & Company, with a price target of $82.00. The company...

BMO Capital Sticks to Its Hold Rating for Merck & Company (MRK)

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Merck KGaA today and set a price target of €155.00. The company’s shares closed last ...

Merck KGaA (0O14) Gets a Buy from J.P. Morgan

Marker Therapeutics (($MRKR)) announced an update on their ongoing clinical study. Marker Therapeutics is conducting a Phase 1 study titled ‘A Phas...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRK	$97.76	+2.94%	23.18M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRK	$97.76	+2.9%	23.18M
3
4
5
6

MRK

MRK

Get Merck & Company Inc. Data in Excel

Get Merck & Company Inc. Data in Excel